The FDA expressed concern that the relatively
free over-the-counter access to acetaminophencontaining
products and the lack of healthcare provider
control in the outpatient setting were part of the
problem. These access and control issues should not
apply to IV acetaminophen in the inpatient hospital
setting in which it will be administered.